<scp>SARS</scp>–<scp>CoV</scp>‐2 Infection and <scp>COVID</scp>‐19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta‐Analysis
-
- Richard Conway
- St. James's Hospital and Trinity College Dublin Ireland
-
- Alyssa A. Grimshaw
- Yale University New Haven Connecticut
-
- Maximilian F. Konig
- The Johns Hopkins University School of Medicine Baltimore Maryland
-
- Michael Putman
- The Medical College of Wisconsin Milwaukee
-
- Alí Duarte‐García
- Mayo Clinic Rochester Minnesota
-
- Leslie Yingzhijie Tseng
- Yale School of Medicine New Haven Connecticut
-
- Diego M. Cabrera
- Yale School of Medicine New Haven Connecticut
-
- Yu Pei Eugenia Chock
- Yale School of Medicine New Haven Connecticut
-
- Huseyin Berk Degirmenci
- Tufts University School of Medicine Boston Massachusetts
-
- Eimear Duff
- St. James's Hospital Dublin Ireland
-
- Bugra Han Egeli
- Boston University School of Medicine, Boston, Massachusetts and University of Southern California Los Angeles
-
- Elizabeth R. Graef
- Boston University School of Medicine Boston Massachusetts
-
- Akash Gupta
- Yale School of Medicine New Haven Connecticut
-
- Patricia Harkins
- St. James's Hospital Dublin Ireland
-
- Bimba F. Hoyer
- University Hospital Schleswig‐Holstein Campus Kiel Germany
-
- Arundathi Jayatilleke
- Temple University Philadelphia Pennsylvania
-
- Shangyi Jin
- Chinese Academy of Medical Sciences and Peking Union Medical College and National Clinical Research Center for Dermatologic and Immunologic Diseases Beijing China
-
- Christopher Kasia
- The Medical College of Wisconsin Milwaukee
-
- Aneka Khilnani
- George Washington University School of Medicine and Health Sciences Washington DC
-
- Adam Kilian
- Saint Louis University School of Medicine St. Louis Missouri
-
- Alfred H. J. Kim
- Washington University School of Medicine St. Louis Missouri
-
- Chung Mun Alice Lin
- National Institute of Health Research and Newcastle University Newcastle‐upon‐Tyne UK
-
- Candice Low
- St. Vincent's University Hospital Dublin Ireland
-
- Laurie Proulx
- Canadian Arthritis Patient Alliance Ottawa Ontario Canada
-
- Sebastian E. Sattui
- University of Pittsburgh Medical Center Pittsburgh Pennsylvania
-
- Namrata Singh
- University of Washington Seattle
-
- Jeffrey A. Sparks
- Brigham and Women's Hospital and Harvard Medical School Boston Massachusetts
-
- Herman Tam
- Stollery Children's Hospital and University of Alberta Edmonton Alberta Canada
-
- Manuel F. Ugarte‐Gil
- Universidad Cientifica del Sur and Hospital Guillermo Almenara Irigoyen Seguro Social de Salud del Peru Lima Peru
-
- Natasha Ung
- Campbelltown Hospital, Campbelltown and University of Western Sydney New South Wales Australia
-
- Kaicheng Wang
- Yale School of Medicine and Yale School of Public Health New Haven Connecticut
-
- Leanna M. Wise
- University of Southern California Los Angeles
-
- Ziyi Yang
- Chinese Academy of Medical Sciences and Peking Union Medical College and National Clinical Research Center for Dermatologic and Immunologic Diseases Beijing China
-
- Kristen J. Young
- University of Texas Southwestern Dallas
-
- Jean W. Liew
- Boston University School of Medicine Boston Massachusetts
-
- Rebecca Grainger
- University of Otago Wellington New Zealand
-
- Zachary S. Wallace
- Harvard Medical School Boston Massachusetts
-
- Evelyn Hsieh
- VA Connecticut Healthcare System West Haven Connecticut
Abstract
<jats:sec><jats:title>Objective</jats:title><jats:p>The relative risk of SARS–CoV‐2 infection and COVID‐19 disease severity among people with rheumatic and musculoskeletal diseases (RMDs) compared to those without RMDs is unclear. This study was undertaken to quantify the risk of SARS–CoV‐2 infection in those with RMDs and describe clinical outcomes of COVID‐19 in these patients.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We conducted a systematic literature review using 14 databases from January 1, 2019 to February 13, 2021. We included observational studies and experimental trials in RMD patients that described comparative rates of SARS–CoV‐2 infection, hospitalization, oxygen supplementation/intensive care unit (ICU) admission/mechanical ventilation, or death attributed to COVID‐19. Methodologic quality was evaluated using the Joanna Briggs Institute critical appraisal tools or the Newcastle‐Ottawa scale. Risk ratios (RRs) and odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated, as applicable for each outcome, using the Mantel‐Haenszel formula with random effects models.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Of the 5,799 abstracts screened, 100 studies met the criteria for inclusion in the systematic review, and 54 of 100 had a low risk of bias. Among the studies included in the meta‐analyses, we identified an increased prevalence of SARS–CoV‐2 infection in patients with an RMD (RR 1.53 [95% CI 1.16–2.01]) compared to the general population. The odds of hospitalization, ICU admission, and mechanical ventilation were similar in patients with and those without an RMD, whereas the mortality rate was increased in patients with RMDs (OR 1.74 [95% CI 1.08–2.80]). In a smaller number of studies, the adjusted risk of outcomes related to COVID‐19 was assessed, and the results varied; some studies demonstrated an increased risk while other studies showed no difference in risk in patients with an RMD compared to those without an RMD.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Patients with RMDs have higher rates of SARS–CoV‐2 infection and an increased mortality rate.</jats:p></jats:sec>
Journal
-
- Arthritis & Rheumatology
-
Arthritis & Rheumatology 74 (5), 766-775, 2022-03-28
Wiley
- Tweet
Details 詳細情報について
-
- CRID
- 1360016866460210560
-
- ISSN
- 23265205
- 23265191
-
- Data Source
-
- Crossref